MAnagement of High Bleeding Risk Patients Post Bioresorbable Polymer Coated STEnt Implantation With an AbbReviated Versus Prolonged DAPT Regimen
ID: NCT03023020
The study compares two lengths of medication therapy (a shortened versus a prolonged dual antiplatelet therapy) in order to prevent thrombus (blood cloth) formation after the successfully treatment for coronary heart disease with a drug covered stent (metallic tube).
This comparison will be done in patients who, compared to the average patient, are more likely to suffer from complications on antiplatelet therapy (bleeding). Both durations are within the current medical recommendations. The aim of this study is to help improve further standard antiplatelet duration guidelines.
The study design is an investigator-initiated, randomized, multi-center, clinical trial to be conducted in 111 interventional cardiology centers managed by CERC in across the globe excluding USA and in total in 140 centers worldwide. The study includes 2 x 2150 patients (i.e. 4300 patients) Randomization will occur at one month after the PCI procedure. The expected duration of participation for each patient is 14 months.
Last publications:
Sponsor
Primary endpoints
This study has 3 primary endpoints:
- Net adverse clinical endpoints (NACE) defined as a composite of all-cause death, myocardial infarction, stroke and bleeding events defined as BARC 3 or 5
- Major adverse cardiac and cerebral events (MACCE) defined as a composite of all-cause death, myocardial infarction and stroke
- Major or clinically relevant non-major bleeding (MCB) defined as a composite of type 2, 3 and 5 BARC bleeding events
Countries
30: Argentina, Australia, Austria, Bahrain, Bangladesh, Belgium, Bulgaria, Czechia, Denmark, Estonia, France, Germany, Hungary, India, Israel, Italy, Japan, Netherlands, Poland, Saudi Arabia, Serbia, Singapore, Slovenia, South Korea, Spain, Sweden, Switzerland, United Kingdom & Vietnam
Number of investigational sites
138
Number of patients
4579
